Insider Trading Alert - ICPT, SPTN And CME Traded By Insiders

Yesterday, Aug. 2, 2016, 97 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.70 to $50,903,280.00.

Highlighted Stocks Traded by Insiders:

Intercept Pharmaceuticals (ICPT) - FREE Research Report

McMinn Rachel, who is Chief Strategy Officer at Intercept Pharmaceuticals, sold 125 shares at $176.56 on Aug. 2, 2016. Following this transaction, the Chief Strategy Officer owned 13,861 shares meaning that the stake was reduced by 0.89% with the 125-share transaction.

The shares most recently traded at $169.72, down $6.84, or 4.03% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 1,284
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 1,535
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 3,180

The average volume for Intercept Pharmaceuticals has been 516,900 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are up 15.86% year-to-date as of the close of trading on Friday.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Currently, there are 8 analysts who rate Intercept Pharmaceuticals a buy, 3 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone